DOCSLIB.ORG

Structure-Function Studies of Xanthine Oxidoreductase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structure-Function Studies of Xanthine Oxidoreductase STRUCTURE-FUNCTION STUDIES OF XANTHINE OXIDOREDUCTASE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in the Graduate School of The Ohio State University By James Michael Pauff The Ohio State University 2008 Dissertation Committee: Professor Virginia Sanders, Advisor on Record Approved By Professor Russ Hille, Graduate Advisor Associate Professor Charles E. Bell _______________ Professor Allan Yates Advisor Integrated Biomedical Science Graduate Program ABSTRACT Xanthine oxidoreductase (XOR) is a 290 kDa molybdenum-containing enzyme that catalyzes the final two steps in human purine catabolism, taking hypoxanthine to xanthine and then on to uric acid. The enzyme exists as a homodimer, with each monomer possessing a catalytic active site that contains one molybdenum atom coordinated to a pterin ring via an enedithiolate side chain. Each monomer also contains two [2Fe2S] clusters and one equivalent of FAD. These centers form an electron transfer chain as electrons are passed sequentially from the molybdenum to the FAD via the iron-sulfur clusters. The molybdenum center cycles from MoVI to MoIV and back during catalysis, passing through an occasional MoV intermediate state. Electrons are passed from the flavin site out of the enzyme to either NAD+ or molecular oxygen. XOR is initially expressed as a dehydrogenase (xanthine dehydrogenase, XDH) with a strong preference for reducing NAD+ to NADH, + although it can reduce O2 under conditions of low NAD concentrations. Under certain conditions, XDH can be converted by oxidation and/or limited proteolysis to an oxidase form (xanthine oxidase, XO) that utilizes O2 exclusively as the terminal electron acceptor, thereby generating superoxide and other reactive oxygen species. The oxidase is formed primarily during hypoxia or ischemia, and the corresponding increase in reactive oxygen species has lead to investigation of the enzyme’s role in the pathophysiological mechanism of ischemia-reperfusion. The production of uric acid by XOR makes the enzyme a primary target in hyperuricemia, and it is this ii therapeutic intervention for which allopurinol has been used for over 60 years. The prevalence of XOR in mechanisms leading to some human diseases and the unique chemistry by which the enzyme catalyzes the production of uric acid makes this enzyme system an interesting subject of biochemical investigation. We have sought here to understand the structure and function of xanthine oxidoreductase, focusing on the nature of the molybdenum-containing active site as well as innate functional differences between the two forms of the enzyme. Our crystallographic and spectroscopic studies provide insight into the mechanism of XOR catalysis as well as the roles of XOR in human pathology. iii DEDICATION To my parents, Neil and Deborah Pauff, my brother Frank, to my fiancé Beth, and to my entire family iv ACKNOWLEDGMENTS I would first like to thank my parents for countless hours (and dollars) spent raising, teaching, correcting, guiding, and being patient with me through the years. Many lessons that I only realized much later have helped carry me and sustain me throughout my educational training. I would like to thank Dr. Russ Hille for his support, guidance, and patience during my research training in his laboratories. My sometimes sporadic ideas were met with encouragement and a willingness to let me go my own way, even though in some instances that meant a waste of resources. Thank you for allowing me the independence to learn from my own successes and mistakes, and to grow as a researcher along the way. I would also like to thank Craig Hemann for his efforts, consultation, and advice, particularly in the early stages of my dissertation work. You remain a tremendous resource. To Dr. Silke Leimkühler, thank you for the collaboration and efforts with the xanthine dehydrogenase system. To Dr. Charles Bell, thank you for the many hours of guidance and assistance with the crystallographic work. Without your advice we would not have any structures. I would also like to thank Dr. Allan Yates for his guidance and critical evaluation of my research and training as an MD/PhD student. To the entire Hille lab past and present, thank you for the consultations and the laughter as we worked alongside one another. v VITA 1981 Born – Bluffton, OH 2004 B.S. Chemistry, B.S. Biochemistry, B.A. Zoology Miami University Oxford, OH 2004 – Present Graduate Fellow, Graduate Research Associate Medical Scientist Program The Ohio State University Columbus, OH 2007 – 2008 Junior Specialist Department of Biochemistry University of California at Riverside Riverside, CA PUBLICATIONS Pauff, J.M., Hemann, C.F., Jünemann, N., Leimkühler, S., and Hille, R. (2007) The Role of Arginine 310 in Catalysis and Substrate Specificity in Xanthine Dehydrogenase from Rhodobacter capsulatus. J. Biol. Chem. 282, 12785 – 12790. Pauff, J.M., Zhang, J., Bell, C.E., and Hille, R. (2008) Substrate Orientation in Xanthine Oxidase: CRYSTAL STRUCTURE OF ENZYME IN REACTION WITH 2-HYDROXY-6-METHYLPURINE. J. Biol. Chem. 283, 4818 – 4824. Fields of Study: Biochemistry, Enzymology, Macromolecular X-ray Crystallography Major Field: Integrated Biomedical Science Graduate Program vi TABLE OF CONTENTS Abstract………………………………………………………………………………..ii Dedication…………………………………………………………………………….iv Acknowledgments……………………………..………………………………………v Vita……………………………………………………………………………………vi List of Figures…………………………………………………………………………x List of Tables…………………………………………………………………………xii Abbreviations………………………………………………………………………..xiii References…………………………………………………………………………..154 Chapters: 1. Introduction………………………………………………………………………..1 1.1. General Background………………………………………………………….1 1.1.1. Molybdenum…………………………………………………………..1 1.1.2. Molybdenum in biology and molybdenum-containing enzymes….......2 1.1.3. Xanthine oxidoreductase………………………………………………4 1.2. Xanthine oxidoreductase in physiology………………………………………5 1.3. Xanthine oxidoreductase in pathology………………………………………..7 1.3.1. Inhibition of XOR……………………………………………………..9 1.4. Structure of xanthine oxidoreductase………………………………………..12 1.5. Mechanism of catalysis and the oxidation-reduction chemistry chemistry of XOR…………………………………………………………………………15 1.5.1. The molybdenum-containing active site……………………………..17 1.5.2. Oxidative and reductive half-reactions of XOR catalysis……………22 1.5.3. Active site residues in the molybdenum site…………………………25 1.5.4. The pterin cofactor, iron-sulfur clusters, and the flavin site…………29 vii 1.6. Preparation and Isolation of Xanthine Oxidoreductase in the Present Studies 32 1.6.1. Bovine xanthine oxidase and xanthine dehydrogenase………………32 1.6.2. Xanthine dehydrogenase from Rhodobacter capsulatus……………..34 1.6.3. Activity-to-flavin determination and percentage of active enzyme….34 1.6.4. Inactive and inactivating XOR……………………………………….35 2. The Role of Arginine 310 in the Active Site of Xanthine Dehydrogenase from Rhodobacter capsulatus………………………………………………………….37 2.1. Introduction………………………………………………………………….37 2.2. Materials and Methods………………………………………………………42 2.2.1. Preparation of wild-type and mutant xanthine dehydrogenase from Rhodobacter capsulatus………………………………………………...42 2.2.2. Rapid-reaction experiments…………………………………………..43 2.2.3. Data acquisition and analysis………………………………………...43 2.3. Results and Discussion………………………………………………………44 3. Substrate Orientation in Xanthine Oxidase from Bos taurus, Crystal Structure with 2-hydroxy-6-methylpurine………………………………………………….50 3.1. Introduction………………………………………………………………….50 3.2. Materials and Methods………………………………………………………51 3.2.1. Materials……………………………………………………………...51 3.2.2. Preparation and isolation of bovine xanthine oxidase………………..51 3.2.3. Crystal growth, diffraction, and data acquisition…………………….52 3.2.4. Data processing and refinement……………………………………...55 3.3. Results and Discussion………………………………………………………56 3.3.1. Overall structure of xanthine oxidase with 2-hydroxy-6-methylpurine………………………………………...56 3.3.2. 2-hydroxy-6-methylpurine in the active sites of xanthine oxidase…..60 4. Xanthine and Lumazine in the Active Site of Xanthine Oxidase from Bos Taurus………………………………………………………………….64 4.1. Introduction………………………………………………………………….64 4.2. Materials and Methods………………………………………………………68 4.2.1. Materials……………………………………………………………...68 4.2.2. Preparation of bovine xanthine oxidase and the desulfo-form……….68 4.2.3. Crystal growth, diffraction, and data acquisition…………………….69 4.2.4. Data processing and refinement……………………………………...70 4.3. Results and Discussion………………………………………………………71 4.3.1. Xanthine oxidase with lumazine……………………………………..71 4.3.2. Desulfo-xanthine oxidase with xanthine……………………………..75 5. Activity of Xanthine Dehydrogenase versus Xanthine Oxidase in the Range of Physiological pH…………………………………………………………………91 5.1. Introduction………………………………………………………………….91 viii 5.2. Materials and Methods………………………………………………………96 5.2.1. Preparation of bovine xanthine oxidase and bovine xanthine dehydrogenase…………………………………………………………..96 5.2.2. Steady-state kinetics and construction of the pH profile for bovine XDH…………………………………………………………………….98 5.2.3. Consumption of oxygen by XDH in the absence of NAD+………….99 5.3. Results and Discussion……………………………………………………..100 5.3.1. pH profiles for the two forms of XOR……………………………...100 5.3.2. Oxygen consumption by XDH……………………………………...105 6. Inhibition Studies of Xanthine Oxidase………………………………………...109 6.1. Introduction………………………………………………………………...109 6.2. Materials and Methods……………………………………………………..119 6.2.1. Compounds and reagents……………………………………………119 6.2.2. Isolation
Load more

Recommended publications
  • Nitrate Reductase from a Neurospora Mutant and a Component of Molybdenum-Enzymes (Nitrogenases/Sulfite Oxidase/E
    Proc. Nat. Acad. Sci. USA Vol. 68, No. 12, pp. 3242-3246, December 1971 In Vitro Formation of Assimilatory Reduced Nicotinamide Adenine Dinucleotide Phosphate: Nitrate Reductase from a Neurospora Mutant and a Component of Molybdenum-Enzymes (nitrogenases/sulfite oxidase/E. coli) ALVIN NASON, KUO-YUNG LEE, SU-SHU PAN, PAUL A. KETCHUM*, ANTONIO LAMBERTI, AND JAMES DEVRIES McCollum-Pratt Institute, The Johns Hopkins University, Baltimore, Maryland 21218. Communicated by Earl R. Stadttman, September 16, 19711 ABSTRACT An active Neurospora-like assimilatory denum moiety. The second component could also be NADPH-nitrate reductase (EC 1.6.6.2), which can be formed in vitro by incubation of extracts of nitrate-in- supplied by the individual molybdenum-enzymes bovine duced Neurospora crassa mutant nit-i with extracts of milk and intestinal xanthine oxidases, chicken liver dehydro- (a) certain other nonallelic nitrate reductase mutants, (b) genase, and rabbit liver aldehyde oxidase (8), provided they uninduced wild type, or (c) xanthine oxidizing and liver were subjected to prior acidification, a treatment known to aldehyde-oxidase systems was also formed by combination dissociate some proteins into their subunits (9-11). (How- of the nit-i extract with other acid-treated enzymes known to contain molybdenum. These molybdenum ever, sodium molybdate and some 20 different partially puri- enzymes included (a) nitrogenase, or its molybdenum- fied enzymes that do not contain molybdenum were inactive.) iron protein, from Clostridium, Azotobacter, and
    [Show full text]
  • Nucleotide Degradation
    Nucleotide Degradation Nucleotide Degradation The Digestion Pathway • Ingestion of food always includes nucleic acids. • As you know from BI 421, the low pH of the stomach does not affect the polymer. • In the duodenum, zymogens are converted to nucleases and the nucleotides are converted to nucleosides by non-specific phosphatases or nucleotidases. nucleases • Only the non-ionic nucleosides are taken & phospho- diesterases up in the villi of the small intestine. Duodenum Non-specific phosphatases • In the cell, the first step is the release of nucleosides) the ribose sugar, most effectively done by a non-specific nucleoside phosphorylase to give ribose 1-phosphate (Rib1P) and the free bases. • Most ingested nucleic acids are degraded to Rib1P, purines, and pyrimidines. 1 Nucleotide Degradation: Overview Fate of Nucleic Acids: Once broken down to the nitrogenous bases they are either: Nucleotides 1. Salvaged for recycling into new nucleic acids (most cells; from internal, Pi not ingested, nucleic Nucleosides acids). Purine Nucleoside Pi aD-Rib 1-P (or Rib) 2. Oxidized (primarily in the Phosphorylase & intestine and liver) by first aD-dRib 1-P (or dRib) converting to nucleosides, Bases then to –Uric Acid (purines) –Acetyl-CoA & Purine & Pyrimidine Oxidation succinyl-CoA Salvage Pathway (pyrimidines) The Salvage Pathways are in competition with the de novo biosynthetic pathways, and are both ANABOLISM Nucleotide Degradation Catabolism of Purines Nucleotides: Nucleosides: Bases: 1. Dephosphorylation (via 5’-nucleotidase) 2. Deamination and hydrolysis of ribose lead to production of xanthine. 3. Hypoxanthine and xanthine are then oxidized into uric acid by xanthine oxidase. Spiders and other arachnids lack xanthine oxidase.
    [Show full text]
  • 35 Disorders of Purine and Pyrimidine Metabolism
    35 Disorders of Purine and Pyrimidine Metabolism Georges van den Berghe, M.- Françoise Vincent, Sandrine Marie 35.1 Inborn Errors of Purine Metabolism – 435 35.1.1 Phosphoribosyl Pyrophosphate Synthetase Superactivity – 435 35.1.2 Adenylosuccinase Deficiency – 436 35.1.3 AICA-Ribosiduria – 437 35.1.4 Muscle AMP Deaminase Deficiency – 437 35.1.5 Adenosine Deaminase Deficiency – 438 35.1.6 Adenosine Deaminase Superactivity – 439 35.1.7 Purine Nucleoside Phosphorylase Deficiency – 440 35.1.8 Xanthine Oxidase Deficiency – 440 35.1.9 Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency – 441 35.1.10 Adenine Phosphoribosyltransferase Deficiency – 442 35.1.11 Deoxyguanosine Kinase Deficiency – 442 35.2 Inborn Errors of Pyrimidine Metabolism – 445 35.2.1 UMP Synthase Deficiency (Hereditary Orotic Aciduria) – 445 35.2.2 Dihydropyrimidine Dehydrogenase Deficiency – 445 35.2.3 Dihydropyrimidinase Deficiency – 446 35.2.4 Ureidopropionase Deficiency – 446 35.2.5 Pyrimidine 5’-Nucleotidase Deficiency – 446 35.2.6 Cytosolic 5’-Nucleotidase Superactivity – 447 35.2.7 Thymidine Phosphorylase Deficiency – 447 35.2.8 Thymidine Kinase Deficiency – 447 References – 447 434 Chapter 35 · Disorders of Purine and Pyrimidine Metabolism Purine Metabolism Purine nucleotides are essential cellular constituents 4 The catabolic pathway starts from GMP, IMP and which intervene in energy transfer, metabolic regula- AMP, and produces uric acid, a poorly soluble tion, and synthesis of DNA and RNA. Purine metabo- compound, which tends to crystallize once its lism can be divided into three pathways: plasma concentration surpasses 6.5–7 mg/dl (0.38– 4 The biosynthetic pathway, often termed de novo, 0.47 mmol/l). starts with the formation of phosphoribosyl pyro- 4 The salvage pathway utilizes the purine bases, gua- phosphate (PRPP) and leads to the synthesis of nine, hypoxanthine and adenine, which are pro- inosine monophosphate (IMP).
    [Show full text]
  • Independent Discovery in Biology: Investigating Styles of Scientific Research
    Medical History, 1993, 37: 432-441. INDEPENDENT DISCOVERY IN BIOLOGY: INVESTIGATING STYLES OF SCIENTIFIC RESEARCH by NICHOLAS RUSSELL * INTRODUCTION The fact that discoveries are often made independently is a commonplace of the history and sociology of science. Analysis of independent discovery has potential for evaluating the relative importance of social and individual components in the conduct of scientific research.' For instance, in a classic paper, Barber and Fox2 discussed the independent discovery of a bizarre phenomenon by two scientists. Aaron Kellner and Lewis Thomas both found that injections of the enzyme papain caused the upright ears of rabbits to droop over their heads like spaniels'. At first neither could find an explanation for it. Both abandoned the search and Kellner never returned to it, even though he went on to use the floppy ear response as a technical assay for measuring the potency of papain samples. Lewis Thomas did look into it again and discovered that papain completely altered the structure of the matrix of cartilage, not only in the ears but everywhere else in the animal as well. Both Thomas and Kellner had originally missed these changes because they had assumed that cartilage was a stable and uninteresting tissue. Barber and Fox concluded that Thomas persisted with the problem because it played a role in his developing research while the floppy-eared phenomenon was irrelevant to Kellner's interests. Barber and Fox hinted that more personal factors were involved as well, a theme expanded by Thomas in a later autobiographical essay.3 Thomas had found the collapsed ears amusing.
    [Show full text]
  • Pro-Aging Effects of Xanthine Oxidoreductase Products
    antioxidants Review Pro-Aging Effects of Xanthine Oxidoreductase Products , , Maria Giulia Battelli y , Massimo Bortolotti y , Andrea Bolognesi * z and Letizia Polito * z Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; [email protected] (M.G.B.); [email protected] (M.B.) * Correspondence: [email protected] (A.B.); [email protected] (L.P.); Tel.: +39-051-20-9-4707 (A.B.); +39-051-20-9-4729 (L.P.) These authors contributed equally. y Co-last authors. z Received: 22 July 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: The senescence process is the result of a series of factors that start from the genetic constitution interacting with epigenetic modifications induced by endogenous and environmental causes and that lead to a progressive deterioration at the cellular and functional levels. One of the main causes of aging is oxidative stress deriving from the imbalance between the production of reactive oxygen (ROS) and nitrogen (RNS) species and their scavenging through antioxidants. Xanthine oxidoreductase (XOR) activities produce uric acid, as well as reactive oxygen and nitrogen species, which all may be relevant to such equilibrium. This review analyzes XOR activity through in vitro experiments, animal studies and clinical reports, which highlight the pro-aging effects of XOR products. However, XOR activity contributes to a regular level of ROS and RNS, which appears essential for the proper functioning of many physiological pathways. This discourages the use of therapies with XOR inhibitors, unless symptomatic hyperuricemia is present.
    [Show full text]
  • The Link Between Purine Metabolism and Production of Antibiotics in Streptomyces
    antibiotics Review The Link between Purine Metabolism and Production of Antibiotics in Streptomyces Smitha Sivapragasam and Anne Grove * Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA; [email protected] * Correspondence: [email protected] Received: 10 May 2019; Accepted: 3 June 2019; Published: 6 June 2019 Abstract: Stress and starvation causes bacterial cells to activate the stringent response. This results in down-regulation of energy-requiring processes related to growth, as well as an upregulation of genes associated with survival and stress responses. Guanosine tetra- and pentaphosphates (collectively referred to as (p)ppGpp) are critical for this process. In Gram-positive bacteria, a main function of (p)ppGpp is to limit cellular levels of GTP, one consequence of which is reduced transcription of genes that require GTP as the initiating nucleotide, such as rRNA genes. In Streptomycetes, the stringent response is also linked to complex morphological differentiation and to production of secondary metabolites, including antibiotics. These processes are also influenced by the second messenger c-di-GMP. Since GTP is a substrate for both (p)ppGpp and c-di-GMP, a finely tuned regulation of cellular GTP levels is required to ensure adequate synthesis of these guanosine derivatives. Here, we discuss mechanisms that operate to control guanosine metabolism and how they impinge on the production of antibiotics in Streptomyces species. Keywords: c-di-GMP; guanosine and (p)ppGpp; purine salvage; secondary metabolism; Streptomycetes; stringent response 1. Introduction Bacteria experience constant challenges, either in the environment or when infecting a host. They utilize various mechanisms to survive such stresses, which may include changes in temperature, pH, or oxygen content as well as limited access to carbon or nitrogen sources.
    [Show full text]
  • Xanthine Oxidase Assay (XO) Cat
    Xanthine Oxidase Assay (XO) Cat. No. 8458 100 Tests in 96-well plate Introduction Xanthine Oxidase (XO) located predominantly in the liver and intestine in mammalian tissues and catalyzes the hydroxylation of hypoxanthine to xanthine and then to uric acid and hydrogen peroxide. XO activity is normally very low in blood and liver injury can result in the release of XO into blood. XO activity or expression can be up-regulated in gout and cardiovascular disease. This colorimetric assay is based on XO-catalyzed oxidation of xanthine, in which the formed hydrogen peroxide is catalyzed by peroxidase and reacts with 4-aminoantipyrine to form the product dye. The color intensity of the reaction product at 550nm is directly proportional to XO activity in the sample. Kit Components Cat. No. # of vials Reagent Quantity Storage 8458a 1 Assay buffer 10 mL 4°C 8458b 1 Xanthine Oxidase standard 0.2 mL -20°C 8458c 1 Xanthine 2.0 mL -20°C 8458d 1 Substrate mix 1.6 mL -20°C 8458e 1 Enzyme mix 0.1 mL -20°C Product Use The Xanthine Oxidase Assay kit measures the xanthine oxidase level of different types of samples, such as serum, plasma, tissues. This product is for research purposes only and not for use in animals, humans, or diagnostic procedures. Quality Control Serially diluted xanthine oxidase solutions with concentrations ranging from 7.81 to 125 mU/mL are measured with the ScienCell™ Xanthine Oxidase Assay kit. The increase in OD550nm is monitored as a function of time (Figure 1) and the resulting standard curve of ∆OD550nm/min vs xanthine oxidase activity are plotted (Figure 2).
    [Show full text]
  • Xanthine Oxidoreductase in Cancer
    Cancer Medicine Open Access REVIEW Xanthine oxidoreductase in cancer: more than a differentiation marker Maria Giulia Battelli, Letizia Polito, Massimo Bortolotti & Andrea Bolognesi Department of Experimental, Diagnostic and Specialty Medicine – DIMES, Alma Mater Studiorum – University of Bologna, General Pathology Unit, Via S. Giacomo 14, 40126 Bologna, Italy Keywords Abstract Differentiation, oncogenesis, reactive oxygen and nitrogen species, uric acid, xanthine Human xanthine oxidoreductase (XOR) catalyzes the last two steps of purine oxidoreductase catabolism and is present in two interconvertible forms, which may utilize O2 or NAD+ as electron acceptors. In addition to uric acid, XOR products may Correspondence comprise reactive oxygen and nitrogen species that have many biologic effects, Letizia Polito, Department of Experimental, including inflammation, endothelial dysfunction, and cytotoxicity, as well as Diagnostic and Specialty Medicine – DIMES, mutagenesis and induction of proliferation. XOR is strictly modulated at the Alma Mater Studiorum – University of Bologna, General Pathology Unit, Via S. transcriptional and post-­translational levels, and its expression and activity are Giacomo 14, 40126 Bologna, Italy. highly variable in cancer. Xanthine oxidoreductase (XOR) expression has been Tel: +39 051 2094700; Fax: +39 051 2094746; negatively associated with a high malignity grade and a worse prognosis in E-mail: [email protected] neoplasms of the breast, liver, gastrointestinal tract, and kidney, which normally express a high level of XOR protein. However, the level of XOR expression Funding Information may be associated with a worse outcome in cancer of low XOR-expressing­ cells, This work was supported by the Pallotti in relation to the inflammatory response elicited through the tissue damage Legacies for Cancer Research.
    [Show full text]
  • Monitoring the Redox Status in Multiple Sclerosis
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 31 July 2020 doi:10.20944/preprints202007.0737.v1 Review Monitoring the Redox Status in Multiple Sclerosis Masaru Tanaka 1,2 and László Vécsei 1,2,* 1 MTA-SZTE, Neuroscience Research Group, Semmelweis u. 6, Szeged, H-6725 Hungary; [email protected] 2 Department of Neurology, Interdisciplinary Excellence Centre, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary * Correspondence: [email protected]; Tel.: +36-62-545-351 Received: date; Accepted: date; Published: date Abstract: Worldwide, over 2.2 million people are suffered from multiple sclerosis (MS), a multifactorial demyelinating disease of the central nervous system, characterized by multifocal inflammatory or demyelinating attacks associated with neuroinflammation and neurodegeneration. The blood, cerebrospinal fluid, and postmortem brain samples of MS patients evidenced the presence of reduction-oxidation (redox) homeostasis disturbance such as the alternations of oxidative and antioxidative enzyme activities and the presence of degradation products. This review article discussed the components of redox homeostasis including reactive chemical species, oxidative enzymes, antioxidative enzymes, and degradation products. The reactive chemical species covered frequently discussed reactive oxygen/nitrogen species, rarely featured reactive chemicals such as sulfur, carbonyls, halogens, selenium, and nucleophilic species that potentially act as reductive as well as pro-oxidative stressors. The antioxidative enzyme systems covered the nuclear factor erythroid-2-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 (KEAP1) signaling pathway, a possible biomarker sensitive to the initial phase of oxidative stress. Altered components of the redox homeostasis in MS were discussed, some of which turned to be MS subtype- or treatment-specific and thus potentially become diagnostic, prognostic, predictive, and/or therapeutic biomarkers.
    [Show full text]
  • The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 4
    The Story of César Milstein and Monoclonal Antibodies: Introduction Page 1 of 4 Custom Search Search A HEALTHCARE REVOLUTION IN THE MAKING The Story of César Milstein and Monoclonal Antibodies Collated and written by Dr Lara Marks Today six out of ten of the best selling drugs in the world are monoclonal antibody therapeutics. One of these, Humira®, which is a treatment for rheumatoid arthritis and other autoimmune conditions, was listed as the top selling drug across the globe in 2012 with a revenue of US$9.3 billion. Based on its current performance many predict the annual sales of the drug will surpass the peak sales of Lipitor, a treatment for lowering cholesterol, that is the best selling therapeutic of all time. Currently monoclonal antibody drugs make up a third of all new medicines introduced worldwide. http://www.whatisbiotechnology.org/exhibitions/milstein 4/13/2017 PFIZER EX. 1524 Page 1 The Story of César Milstein and Monoclonal Antibodies: Introduction Page 2 of 4 Portrait of César Milstein. Photo credit: Godfrey Argent Studio Monoclonal antibodies are not only successful drugs, but are powerful tools for a wide range of medical applications. On the research front they are essential probes for determining the pathological pathway and cause of diseases like cancer and autoimmune and neurological disorders. They are also used for typing blood and tissue, a process that is vital to blood transfusion and organ transplants. In addition, monoclonal antibodies are critical components in diagnostics, having increased the speed and accuracy of tests. Today the antibodies are used for the detection of multiple conditions, ranging from pregnancy and heart attacks, to pandemic flu, AIDS and diseases like anthrax and smallpox released by biological weapons.
    [Show full text]
  • Xanthine Oxidase Mediates Hypoxia-Inducible Factor-2A Degradation by Intermittent Hypoxia
    Xanthine Oxidase Mediates Hypoxia-Inducible Factor-2a Degradation by Intermittent Hypoxia Jayasri Nanduri*, Damodara Reddy Vaddi, Shakil A. Khan, Ning Wang, Vladislav Makerenko, Nanduri R. Prabhakar Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, Biological Sciences Division, University of Chicago, Chicago, Illinois, United States of America Abstract Sleep-disordered breathing with recurrent apnea produces chronic intermittent hypoxia (IH). We previously reported that IH leads to down-regulation of HIF-2a protein via a calpain-dependent signaling pathway resulting in oxidative stress. In the present study, we delineated the signaling pathways associated with calpain-dependent HIF-2a degradation in cell cultures and rats subjected to chronic IH. Reactive oxygen species (ROS) scavengers prevented HIF-2a degradation by IH and ROS mimetic decreased HIF-2a protein levels in rat pheochromocytoma PC12 cell cultures, suggesting that ROS mediate IH- induced HIF-2a degradation. IH activated xanthine oxidase (XO) by increased proteolytic conversion of xanthine dehydrogenase to XO. ROS generated by XO activated calpains, which contributed to HIF-2a degradation by IH. Calpain- induced HIF-2a degradation involves C-terminus but not the N-terminus of the HIF-2a protein. Pharmacological blockade as well as genetic knock down of XO prevented IH induced calpain activation and HIF-2a degradation in PC12 cells. Systemic administration of allopurinol to rats prevented IH-induced hypertension, oxidative stress and XO activation in adrenal medulla. These results demonstrate that ROS generated by XO activation mediates IH-induced HIF-2a degradation via activation of calpains. Citation: Nanduri J, Vaddi DR, Khan SA, Wang N, Makerenko V, et al.
    [Show full text]
  • Nucleotide Metabolism II
    Nucleotide Metabolism II • Biosynthesis of deoxynucleotides • Salvage Pathway • Catabolism: Purines • Catabolism: Pyrimidines • Feedback inhibition in purine nucleotide biosynthesis CPS II • Cytosolic CPS II uses glutamine as the nitrogen donor to carbamoyl phosphate Regulation of pyrimidine synthesis •CPSII is allosterically regulated: PRPP and IMP are activators Several pyrimidines are inhibitors • Aspartate transcarbamoylase (ATCase) Important regulatory point in prokaryotes Catalyzes the first committed pathway step Allosteric regulators: CTP (-), CTP + UTP (-), ATP (+) • Regulation of pyrimidine nucleotide synthesis in E. coli Biosynthesis of deoxynucleotides • Uses diphosphates (ribo) • Ribonucleotide reducatase • 2 sub-units • R1- reduces, active and two allosteric sites (activity and specificity site) • R2- tyrosine radical carries electrons • removes 2' OH to H Ribonucleotide reductase reaction • removes 2' OH to H • Thioredoxin and NADPH used to regenerate sulfhydryl groups Thymidylate synthesis • UDP ------> dUMP • dUMP --------> dTMP • required THF • methylates uracil Regulation THF • Mammals cannot conjugate rings or synthesize PABA. • So must get in diet. • Sulfonamides effective in bacteria due to competitive inhibition of the incorporation of PABA Cancer Drugs • fluorouracil-- suicide inhibitor of Thy synthase • aminopterin • Methotrexate -- inhibits DHF reductase Salvage of Purines and Pyrimidines • During cellular metabolism or digestion, nucleic acids are degraded to heterocyclic bases • These bases can be salvaged
    [Show full text]